Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, has announced a second commercial agreement with Weill Cornell Medicine to expand the use of its Nociscan platform in a groundbreaking clinical trial. The trial, led by renowned neurosurgeon Roger Härtl, MD, will investigate the long-term effects of lumbar microdiscectomy surgery with and without intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes and intervertebral disc health.
Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It uses magnetic resonance spectroscopy (MRS) data, proprietary signal processing, and augmented intelligence to quantify chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into pain location and has demonstrated a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.
The trial, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial” (IRB Protocol No. 24-09027977), aims to evaluate the natural history of degenerative disc disease (DDD) and inform its treatments. According to Dr. Härtl, the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at Weill Cornell Medicine, “This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”
This is the second trial at Weill Cornell Medicine to incorporate Nociscan. Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the importance of the collaboration: “Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
Chronic low back pain (cLBP) affects approximately 266 million people worldwide, according to a study cited in the announcement (Ravindra VM, Global Spine Journal 2018). The condition is a leading cause of disability, and current diagnostic methods often fail to pinpoint the exact source of pain. Nociscan addresses this gap by objectively quantifying biomarkers linked to disc pain.
The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. For more information on Nociscan, visit Aclarion’s website or view the site map here.
The latest news and updates relating to Aclarion ($ACON) are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
